List of works - Andrea Sartore-Bianchi

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

scientific article

Detection of circulating tumor DNA in early- and late-stage human malignancies

scientific article (publication date: 19 February 2014)

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

scientific article

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

scientific article

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

scientific article published in May 2005

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

scientific article

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

scientific article

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

scientific article

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

scientific article

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

scientific article

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

scientific article published on 30 April 2015

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

scientific article published on 08 September 2009

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

scientific article

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

scientific article

The genomic landscape of response to EGFR blockade in colorectal cancer.

scientific article published on 30 September 2015

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

scientific article published on 07 October 2014

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

scientific article

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

scientific article published on 9 February 2017

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

scientific article

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

scientific article published in February 2014

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

scientific article published on 01 August 2007

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

scientific article published on 01 September 2008

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

scientific article published on 29 November 2017

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

scientific article published on 6 November 2015

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

scientific article

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

scientific article

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

scientific article

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

scientific article published on 09 October 2015

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

scientific article

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

scientific article published on 7 July 2015

Acquired resistance to EGFR-targeted therapies in colorectal cancer

scientific article published on 14 May 2014

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.

scientific article

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

scientific article published on 8 December 2016

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

scientific article

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

scientific article published on 16 June 2016

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

scientific article published on 25 June 2015

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

scientific article

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

scientific article

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

scientific article published in December 2017

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

scientific article

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

scientific article published on 30 November 2011

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

scientific article published on 26 February 2019

EGFR FISH in colorectal cancer: what is the current reality?

scientific article

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory

scientific article published on 6 May 2016

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

scientific article

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

scientific article

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

scientific article published on 24 January 2005

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

scientific article published on 4 September 2017

List of works by Andrea Sartore-Bianchi

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Detection of circulating tumor DNA in early- and late-stage human malignancies

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

The genomic landscape of response to EGFR blockade in colorectal cancer.

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

Acquired resistance to EGFR-targeted therapies in colorectal cancer

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

Adaptive mutability of colorectal cancers in response to targeted therapies

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

EGFR FISH in colorectal cancer: what is the current reality?

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.